PimedBio

  • ABOUT US
    About Us

    We create new treatments
    based on cutting-edge approaches.

    • STARTUP STORY
    • HISTORY
    • LEADERSHIP
    • PARTNERSHIP & COLLABORATION
    • LOCATION
  • PLATFORM
    Platform

    We create new treatments
    based on cutting-edge approaches.

    • Platform Technology
  • PIPELINE
    Pipeline

    We create new treatments
    based on cutting-edge approaches.

    • OVERVIEW
    • Oncology
    • IMMUNOLOGY
  • PR
    PR

    We create new treatments
    based on cutting-edge approaches.

    • News
    • Notice
    • IR
  • CAREER
    CAREER

    We create new treatments
    based on cutting-edge approaches.

    • Recruitment notice
    • Join us
EN
  • KR
  • About Us
    • Startup story
    • History
    • Leadership
    • Partnership & Collaboration
    • Location
  • Platform
    • Platform technology
  • Pipeline
    • Overview
    • Oncology
      • PMB212
      • PMB298
      • Discovery of new drug platforms
    • Immunology
      • PMB702
  • PR
    • News
    • Notice
    • IR
  • Career
    • Recruitment notice
    • Join Us

PR

Shaping Tomorrow with
Next-Gen Therapeutics
  • News
  • Notice
  • IR
  • home
  • PR
  • News

  • 2025.09.01
    파이메드, 암 CSC 표적 'Pin1 저해제' "美1상 승인"
  • 2025.09.01
    케이메디허브, 파이메드바이오㈜와 공동개발 항암제 FDA 1상 IND 승인
  • 2025.04.25
    한독, ‘KRAS TPD’ 등 파이프라인 3건 “AACR 발표”
  • 2024.10.24
    한독, 오픈이노베이션 주제로 창립 70주년 기념 R&D 심포지엄 개최
  • 2024.09.02
    PIMEDBIO - JLABS Korea is Rapidly Energizing the Local Innovation Ecos..
  • 2024.08.20
    초격차 기술로 글로벌 시장 선도할 차세대 K-바이오 기업은?
  • 2024.08.15
    J&J 제이랩스, 서울 사무소 개소…“한국 바이오·의료기기 글로벌 진출 돕겠다”
  • 2024.03.20
    [Nature] 파이메드바이오 KDDF 혁신적인 10대 과제에 선정
  • 2024.02.15
    케이메디허브, 파이메드바이오 '암줄기성 억제 항암신약' 개발 지원
  • 2023.12.13
    파이메드바이오 347개의 국가신약개발사업과제 중 10대 과제 선정
1 2 3

2nd floor, H2233, Healthcare Innovation Park, Bundang Seoul National University Hospital, 172 Dolmaro, Bundang-gu, Seongnam-si, Gyeonggi-do
Tel. +82-31-8039-7240
  • 개인정보처리방침
  • 이메일무단수집거부
Copyright(C) Pimedbio. All Rights Reseved.